| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target fro...
JP Morgan analyst Lilia-Celine Lozada downgrades Treace Medical Concepts (NASDAQ:TMCI) from Neutral to Underweight and lower...
BTIG analyst Ryan Zimmerman downgrades Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral.
Treace Medical Concepts (NASDAQ:TMCI) lowers FY2025 sales outlook from $224.000 million-$230.000 million to $211.000 million-$2...